Effective, safe, and as fast as reasonably possible

For readers who are interested in the processes and the speed with which potential new cancer drugs can be brought to market here in the USA (and other places around the world too), there in an important article in this week’s New England Journal of Medicine. … READ MORE …

Of mice and men all over again …

Yet another set of researchers have found yet another possible new drug that seems to have significant activity in management of prostate cancer — in mice! Whether it will have activity in men is a whole other question. … READ MORE …

What’s a clonal neoantigen when it’s at home? And why is it important?

Many readers of this blog will be aware of the development of immunotherapies like sipuleucel-T (Provenge), CAR-T for the treatment of leukemias, and checkpoint inhibitors in the treatment of some forms of solid tumor (lung cancers, melanoma). … READ MORE …

Guessing the future price of the next major breakthrough in prostate cancer treatment

In an article published on Monday September 28, in Pharmaceutical Executive (a well-known biopharmaceutical industry trade journal) a senior health care public relations executive recently laid out a detailed rationale for why the industry needs to do a better job … READ MORE …

Is drug pricing going to become an election issue in 2016?

As many of our readers will be well aware, The “New” Prostate Cancer InfoLink has long argued that, if the biopharmaceutical industry doesn’t take serious steps to manage the problems of increasing prices that come with no real commensurate value, then someone else will take those steps for them. … READ MORE …

The cost of drugs for the treatment of cancer — in the pressure cooker

According to an announcement this morning from The Mayo Clinic, a group of 118 leading cancer experts has drafted proposals for reducing the high cost of cancer drugs and voiced support for a patient-based grassroots movement demanding action on the issue. … READ MORE …

Assessing the “value” of new drugs in the treatment of [prostate] cancer

Yesterday the American Society of Clinical Oncology (ASCO) issued the initial draft of “a conceptual framework for assessing the value of new cancer therapies based on treatment benefits, toxicities, and costs.” ASCO is interested in getting feedback from its members and from the patient community too. … READ MORE …